Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies Receives Audit Opinion with Going Concern Explanation

PR Newswire September 23, 2016

Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine

PR Newswire September 23, 2016

Earnings Scheduled For September 20, 2016

Benzinga.com  September 20, 2016

Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property

PR Newswire June 6, 2016

Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property

PR Newswire May 26, 2016

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on May 17, 2016

PR Newswire May 17, 2016

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2016 Results

PR Newswire May 12, 2016

Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women's Sexual Health Annual Meeting

PR Newswire February 26, 2016

Palatin Technologies Reports Q2 EPS $(0.08) vs $(0.07) Est.

Press Releases February 16, 2016

Bernstein Upgrades Total to Outperform

Press Releases February 16, 2016

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016

Press Releases February 16, 2016

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results

PR Newswire February 10, 2016

Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction

PR Newswire February 8, 2016

Palatin Technologies To Present At The BIO CEO & Investor Conference

PR Newswire February 4, 2016

Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction

PR Newswire December 10, 2015

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015

PR Newswire November 12, 2015

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015

PR Newswire November 10, 2015

Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting

PR Newswire September 28, 2015

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results

PR Newswire September 21, 2015

Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction

PR Newswire September 21, 2015